Research: CUVELLIER and colleagues,

Listed in Issue 125

Abstract

CUVELLIER and colleagues, Service de neuropediatrie, clinique de pediatrie, hopital Roger-Salengro, centre hospitalier regional et universitaire de Lille, 59037 Lille cedex, France, jc-cuvellier@chru-lille.fr, have reviewed (49 references) drug treatments of migraine attacks in children. Abstract: Migraine occurs in about 5 to 10% of children. Management of acute headache is only one of the parts of the treatment, along with identification of migraine precipitants, adjustments in lifestyle, and when necessary the use of preventive therapy, which can include non-pharmacological (relaxation or biofeedback) or pharmacological treatment. In the acute migraine attack, a single dose of either ibuprofen 10 mg/kg or paracetamol 15 mg/kg has been shown to be effective, with only a few adverse effects. In severe migraine attacks, dihydroergotamine mesylate administered orally (20 to 40 microg/kg) or intravenously (maximum 1 mg/day) may be helpful, but there have been no large placebo-controlled trials of this treatment. Among the different triptans, it is the sumatriptan nasal spray whose efficacy has been best demonstrated.

Background

Methodology

Results

Conclusion

References

Cuvellier JC, Joriot S, Auvin S, Vallee L. Pharmacologic treatment of acute migraine attack in children. Archives de Pediatrie 12 (3): 316-325, Mar 2005.

Munro Hall Clinic 2019

IJCA 2018 New Skyscraper

Scientific and Medical Network 2

Cycle India 2020

Walk on the Wide Side Trek Kenya 2020

Big Heart Bike Ride South Africa 2020

top of the page